Simple. Definitive. Illuminating.
Simple. Definitive. Illuminating.
Transforming catheter ablation of cardiac arrhythmias
LuxCath LLC is a medical technology company founded to address persistent unmet needs in the catheter ablation treatment of cardiac arrhythmias. Its breakthrough technology uses fluorescence and optics to directly view lesions during cardiac ablation procedures. Using LuxCath’s proprietary OmniView™ light-guided ablation catheter, electrophysiologists can for the first time see and assess catheter-tissue contact quality, tissue composition and lesion quality in real time during the procedure, increasing the potential for complete and effective cardiac ablation. LuxCath is a subsidiary of Allied Minds, an innovative U.S. science and technology development and commercialization company.
About Us
Executive Team
Omar Amirana, M.D.
Chief Executive Officer
Omar is a Senior Vice President for Allied Minds who currently also serves as CEO of LuxCath Previously, Omar was a partner at Oxford Bioscience Partners, a Boston-based venture capital firm, where he sourced and led the Series A investment in nFocus Neuromedical, which commercialized a catheter-based aneurysm therapy and was sold to Covidien. Omar is currently on the board of Cardiofocus (AF catheter ablation), previously served as the Vice President of Business Development at St. Jude Medical, and was also co-founder of Cardima (AF ablation; IPO) and Resolution Medical (cardiac mapping), based in Silicon Valley. Omar earned a BS in mechanical engineering from Tufts University and an MD from Eastern Virginia Medical School.Arun Jaganathan
General Manager
Arun Jaganathan is General Manager of LuxCath and a Director at Allied Minds, where he focuses on the life sciences portfolio, including existing subsidiaries and new company formation. Arun’s background includes experience in medical devices, life science tools and drug discovery and development. Prior to joining Allied Minds, Arun was part of the corporate strategy team at Boston Scientific, where he was involved in supporting business development and strategic planning efforts, including M&A and white space market opportunity assessments. Arun also has several years of consulting experience, most recently at Fletcher Spaght Inc., where he advised small to mid-cap life sciences companies on their growth strategy.
Terry Ransbury
Head of Research & Development
Terry has been working in product development since graduating from Duke University in 1983 with degrees in biomedical and electrical engineering. He has worked primarily on Class III (life sustaining) medical devices and their instrumentation for companies including Cordis (JNJ), Ventritex (St. Jude Medical), BioSense-Webster (JNJ), Resolution Medical, and InnerPulse. He is EP Lab Certified and has participated in over 600 human cardiac ablation procedures around the world. He is the primary inventor on many patents for medical devices.
KC Armstrong
Product Development
With nearly 20 years in product development, KC engages in all manner of electrical, software, and mechanical design, system architecture, and technical leadership, and has designed and implemented extensive circuitry and systems for medical, industrial, military, and automotive products. He wields an impressive variety of analytical and design tools, and delights in complex numerical modeling.Cinnamon Larson, PhD
Product Development
Cinnamon has a doctorate in mechanical engineering and over 16 years product development and analysis experience. She is a technical specialist in finite element analysis for design creation, optimization, and failure detection. She has extensive experience in project management, requirement development and documentation, regulatory documentation review and development, validation and verification testing development (FEA and testing) and implementation.Scientific Advisors
Vivek Reddy, M.D.
Director, Cardiac Arrhythmia Service
Mount Sinai Hospital & Mount Sinai Health System
Jeremy Ruskin, M.D.
Founder, Director
Cardiac Arrhythmia Service, Massachusetts General Hospital
David Haines, M.D.
Section Head Heart Rhythm
Beaumont Hospital
Pierre Jais, M.D.
Co-Director
L’institut de Rythmologie et Modélisation Cardiaque,
Bordeaux, France
Andrea Natale, M.D.
Executive Medical Director
Texas Cardiac Arrhythmia Institute at St. David’s Medical Center
Technology
LuxCath’s OmniView light-guided ablation catheter is the only technology that can see into tissue during cardiac ablation and assess catheter-tissue contact and lesion progression in real time. This offers electrophysiologists a simple and more definitive end point for lesion quality, increasing the potential for complete and more effective cardiac ablation.
Cardiac ablation is a well-accepted treatment option for cardiac arrhythmias, performed more than 800,000 times every year globally. Currently, electrophysiologists rely on a range of indirect surrogate end points, such as temperature, power, duration and contact force, to assess lesion quality during the cardiac ablation procedure. However, these surrogate end points have been shown to be variable and potentially unreliable, and they do not directly assess tissue response in real time. Literature has shown single procedure recurrence rates of 20 to 40 percent when ablating atrial fibrillation (AF), the most common form of arrhythmia.
The LuxCath OmniView light-guided catheter delivers and couples light into the tissue via an optical fiber embedded in the ablation catheter to assess tissue metabolic activity. The optical signal can be used to assess stability of catheter-tissue contact, tissue composition and lesion formation. The quality of these lesions is critical, as arrhythmia will recur if the lesions are not complete and uniform across the affected tissue. As lesions are formed, natural tissue fluorescence diminishes, indicating tissue destruction. This feedback mechanism allows the electrophysiologist to better assess the quality of the lesion formed. The next generation of the OmniView is orientation-independent, emitting light and seeing in all directions, allowing for optical signals at all angles of tissue contact.
Latest News
EPLab Digest: Using Fluorescence and Optics to View Lesions During Cardiac Ablation: Interview with Dr. Vivek Reddy
In this feature interview, EP Lab Digest speaks with Vivek Y. Reddy, MD about LuxCath’s emerging technology for real-time tissue contact assessment and lesion monitoring during cardiac ablation. Dr. Reddy is the Director of Cardiac Arrhythmia Services for The Mount Sinai Hospital and the Mount Sinai Health System, and The Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology at Icahn School of Medicine at Mount Sinai.
read moreLuxCath to Showcase Its Breakthrough OmniView Light-Guided Ablation Catheter at HRS 2018
LuxCath, LLC will showcase the next generation of its proprietary OmniView™ light-guided catheter ablation system at the 2018 Heart Rhythm Society (HRS) conference in Boston, May 9 to 12 at the Boston Convention Center.
read moreLuxCath LLC, Demonstrates Promising Results
LuxCath LLC, Demonstrates Promising Results with Optical Tissue Characterization System in Patients during Cardiac Ablation to Cure Arrhythmias; Technology Allows Cardiologists to Continuously “See” Into Heart Tissue with Light
read moreContact Us
LuxCath LLC
100 High St., 28th Floor
Boston, MA 02110
617.419.1800 // info@luxcath.com